353 related articles for article (PubMed ID: 31801379)
41. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
42. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
[No Abstract] [Full Text] [Related]
43. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
44. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
45. Blastic plasmacytoid dendritic cell neoplasm.
Lim D; Goodman H; Rademaker M; Lamont D; Yung A
Australas J Dermatol; 2013 May; 54(2):e43-5. PubMed ID: 23582004
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
Pemmaraju N; Cuglievan B; Lasky J; Kheradpour A; Hijiya N; Stein AS; Meshinchi S; Mullen CA; Angelucci E; Vinti L; Mughal TI; Pawlowska AB
EJHaem; 2024 Feb; 5(1):61-69. PubMed ID: 38406504
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
48. Blastic Plasmacytoid Dendritic Cell Neoplasm: Underlining the importance of an early diagnosis and the use of tagraxofusp therapy before wide dissemination.
Massone C; Raiola AM; Dominietto A; Minetto P; Beltramini S; Cerroni L; Sola S; Angelucci E
Australas J Dermatol; 2021 May; 62(2):e316-e318. PubMed ID: 32757292
[No Abstract] [Full Text] [Related]
49. Targeted diphtheria toxin to treat BPDCN.
FitzGerald DJ
Blood; 2014 Jul; 124(3):310-2. PubMed ID: 25035145
[TBL] [Abstract][Full Text] [Related]
50. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
51. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
52. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement.
Gera S; Dekmezian MS; Duvic M; Tschen JA; Vega F; Cho-Vega JH
Am J Dermatopathol; 2014 Mar; 36(3):244-51. PubMed ID: 24247574
[TBL] [Abstract][Full Text] [Related]
53. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang Y; Sokol L
Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
[TBL] [Abstract][Full Text] [Related]
54. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
55. A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.
Cui XB; Jin J; Pang XL; Li S; Liu CX; Li TT; Peng H; Zhang SM; Li L; Liang WH; Chen YZ; Li F
Int J Clin Exp Pathol; 2014; 7(7):4391-9. PubMed ID: 25120824
[TBL] [Abstract][Full Text] [Related]
56. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
Pemmaraju N
Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
[No Abstract] [Full Text] [Related]
57. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
58. Infiltrative plaques on the temple. Blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Sheng N; Xiong JS; Wang YH; Chen H; Sun JF
Pediatr Dermatol; 2015; 32(2):283-4. PubMed ID: 25801079
[No Abstract] [Full Text] [Related]
59. Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.
Faustmann P; Schroeder JC; Mix L; Harland L; Riedel A; Vogel W; Lengerke C; Wirths S
Front Oncol; 2024; 14():1384172. PubMed ID: 38665943
[TBL] [Abstract][Full Text] [Related]
60. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
